Stuart More
Overview
Explore the profile of Stuart More including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hashlan M, More S, Mukonda E, Brink A
Q J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39869360
Background: One can assess cortical defects on the early images of [99mTc]Tc-MAG3 renography. We aimed to assess interobserver and intraobserver reproducibility for detecting renal cortical defects using [99mTc]Tc-MAG3 for adults...
2.
More S, Sathekge M, Prasad V
Front Nucl Med
. 2024 Oct;
4:1385097.
PMID: 39355214
No abstract available.
3.
Bolcaen J, Combrink N, Spoormans K, More S, Vandevoorde C, Fisher R, et al.
Front Nucl Med
. 2024 Oct;
3:1209823.
PMID: 39355046
Personalised dosimetry based on molecular imaging is a field that has grown exponentially in the last decade due to the increasing success of Radioligand Therapy (RLT). Despite advances in imaging-based...
4.
Hlongwa K, Kolade O, Alnabulsi A, Steyn R, Brink A, Prasad V, et al.
Front Nucl Med
. 2024 Oct;
3:1193880.
PMID: 39355026
Neuroendocrine tumors (NETs) are not commonly diagnosed in children. Metastatic NETs tend to have poor outcomes, and this is seen in adult and pediatric populations. The role of somatostatin receptor...
5.
Mpanya D, Sathekge M, Klug E, Damelin J, More S, Hadebe B, et al.
Front Nucl Med
. 2024 Oct;
3:1224905.
PMID: 39355018
Gallium-68 fibroblast activation protein inhibitor [(Ga)Ga-FAPI] is a new radiopharmaceutical positioning itself as the preferred agent in patients with malignant tumours, competing with 2-Deoxy-2-[18F]fluoro-d-glucose [2-(F)FDG] using positron emission tomography (PET)....
6.
Kolade O, Brink A, Ayeni A, More S, Holness J
Cancer Imaging
. 2024 Apr;
24(1):46.
PMID: 38556864
Background: PSMA PET/CT is the most sensitive molecular imaging modality for prostate cancer (PCa), yet much of the developing world has little or no access to PET/CT. [Tc]Tc-PSMA scintigraphy (PS)...
7.
Abubakar S, More S, Tag N, Olabinjo A, Isah A, Lawal I
Diagnostics (Basel)
. 2023 Jun;
13(12).
PMID: 37370954
Breast cancer in women of African descent tends to be more aggressive with poorer prognosis. This is irrespective of the molecular subtype. [F]FDG PET/CT metrics correlate with breast cancer aggressiveness...
8.
Urbain J, Scott A, Lee S, Buscombe J, Weston C, Hatazawa J, et al.
J Nucl Med
. 2023 May;
64(6):986-991.
PMID: 37142302
No abstract available.
9.
More S, Naiker T, Jacobs N, Oompie F, Prasad V
Clin Nucl Med
. 2023 Mar;
48(5):e217-e218.
PMID: 36881610
Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man...
10.
Brink A, Hlongwa K, More S
Diagnostics (Basel)
. 2023 Jan;
13(2).
PMID: 36673002
This review paper will discuss the use of positron emission tomography/computed tomography (PET/CT) in paediatric oncology. Functional imaging with PET/CT has proven useful to guide treatment by accurately staging disease...